

COMPANY PROFILE

IBA is a world leader in the areas of industrial Sterilization & Ionization, Advanced Radiotherapy and Radioisotopes. The Group's activities can be divided into 2 main sectors:

- industrial sector (sterilization & ionization, including sterilization of medical devices, analytical laboratory testing, food safety, and improvement of material characteristics),
- medical sector (advanced radiotherapy, including dosimetry, and radioisotope production and distribution).

In the industrial sector, IBA masters all the 4 key technologies necessary to meet the diverse application demands of the sterilization and ionization markets: ethylene oxide, cobalt, electron and X-ray technology offering customers equipment or services according to their specific needs.

In 2000, the industrial sector accounted for 69% of IBA's consolidated sales, amounting to 163.6 million EUR.

In the medical sector, IBA develops and industrializes high-tech equipment for the treatment of cancer, including both high-end photon/electron systems such as the "Racetrack" as well as new advanced radiation technology systems such as the IBA Proton Therapy system. Products also include radiotherapy and radiology dosimetry systems ensuring accurate patient dose monitoring and patient positioning.

The medical sector also includes the IBA radioisotope business involving the marketing and sale of cyclotrons to produce radioisotopes used principally for medical imaging and implants for cancer treatment (brachytherapy). In this business area, IBA offers not only a complete range of highly efficient cyclotrons but is also actively developing centers for the distribution of FDG, both in Europe (Lyons, France and Milan, Italy) and the USA.

In fiscal year 2000, IBA's activities in the medical sector accounted for 31% of the total sales figure and stand at 72 million EUR.

IBA (Ion Beam Applications) was founded in 1986 as a spin-off from the nuclear research laboratories of the Catholic University of Louvain-la-Neuve (UCL) in Belgium.

Growing by acquisition in 1998-2000, IBA now operates in 12 countries and on 3 continents. Today, IBA is both an equipment and service provider, owning 37 sterilization & ionization service centers on both sides of the Atlantic and employing more than 1300 people.

IBA is listed on the Brussels Stock Exchange since June 1998 and indexed on NEXT 150. The IBA share is part of the BEL 20 and is listed on the new pan-European Stock Exchange EURONEXT. In 2000, IBA achieved a total sales figure of 236 million EUR and a net current result per share of 0.95 EUR.

OPERATIONAL STRUCTURE

In conformity with the rules of Corporate Governance, the IBA Board consists of four Executive Directors, four Directors representing the shareholders and four independent Directors. The Executive and Strategic Committee consists of Mr Yves Jongen, Chief Research Officer and founder of IBA, Mr Pierre Mottet, Chairman of the Executive and Strategic Committee, Mr Jean-Claude Delobel, Chief Executive Officer and Mr Eric de Lamotte, former Chief Financial Officer.

Reporting to the CEO are the Presidents of the five Business Units: America Operations (responsible for Sterilization & Ionization activities in the


USA and comprising shared services for all businesses in the USA), Sterilization & Ionization EMEAA (Europe, Middle East, Asia, Africa), Advanced Radiotherapy, Radioisotopes and Technology Group (concept development & equipment manufacturing).

At Corporate level reporting to the CEO, there are 8 support functions: Finance, Business Development, Controlling, Communication, Human Resources, Information Systems, Total Quality Management and R&D.




THE EXECUTIVE AND STRATEGIC COMMITTEE (LEFT TO RIGHT):
YVES JONGEN
JEAN-CLAUDE DELOBEL (CEO)
PIERRE MOTTET (CHAIRMAN)
ERIC DE LAMOTTE

The IBA Board



Organization Structure



MISSION & VALUES

IBA Mission Statement

✓ We are a world-wide provider of innovative solutions in the field of health and well-being.

✓ In each of our markets, we want to be the leader, setting new standards.

✓ We do this by focusing on selected applications and by leveraging our expertise in accelerator technology, advanced physics and chemistry.

IBA Values

To reach our mission, we are guided by the following values:

